200 related articles for article (PubMed ID: 32393322)
1. Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis.
Zheng JN; Li Y; Yan YM; Yu Y; Shao WQ; Wang Q
Arthritis Res Ther; 2020 May; 22(1):110. PubMed ID: 32393322
[TBL] [Abstract][Full Text] [Related]
2. The soluble receptor for advanced glycation end products is potentially predictive of pulmonary arterial hypertension in systemic sclerosis.
Atzeni IM; Al-Adwi Y; Doornbos-van der Meer B; Roozendaal C; Stel A; van Goor H; Gan CT; Dickinson M; Timens W; Smit AJ; Westra J; Mulder DJ
Front Immunol; 2023; 14():1189257. PubMed ID: 37409127
[TBL] [Abstract][Full Text] [Related]
3. Myeloid cell-specific deletion of Capns1 prevents macrophage polarization toward the M1 phenotype and reduces interstitial lung disease in the bleomycin model of systemic sclerosis.
Zhang L; Zheng D; Yan Y; Yu Y; Chen R; Li Z; Greer PA; Peng T; Wang Q
Arthritis Res Ther; 2022 Jun; 24(1):148. PubMed ID: 35729674
[TBL] [Abstract][Full Text] [Related]
4. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.
Khanna D; Tashkin DP; Denton CP; Renzoni EA; Desai SR; Varga J
Am J Respir Crit Care Med; 2020 Mar; 201(6):650-660. PubMed ID: 31841044
[TBL] [Abstract][Full Text] [Related]
5. [Expression and clinical significance of plasma exosomal miR-34-5p and miR-142-3p in systemic sclerosis].
Li WG; Gu XD; Weng RQ; Liu SD; Chen C
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 55(6):1022-1027. PubMed ID: 38101783
[TBL] [Abstract][Full Text] [Related]
6. Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease.
Meier C; Freiburghaus K; Bovet C; Schniering J; Allanore Y; Distler O; Nakas C; Maurer B
Sci Rep; 2020 Dec; 10(1):21912. PubMed ID: 33318574
[TBL] [Abstract][Full Text] [Related]
7. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
[TBL] [Abstract][Full Text] [Related]
8. Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis.
Yamakawa H; Hagiwara E; Kitamura H; Yamanaka Y; Ikeda S; Sekine A; Baba T; Iso S; Okudela K; Iwasawa T; Takemura T; Kuwano K; Ogura T
PLoS One; 2016; 11(8):e0161908. PubMed ID: 27564852
[TBL] [Abstract][Full Text] [Related]
9. The potential utility of anterior upper lobe honeycomb-like lesion in interstitial lung disease associated with connective tissue disease.
Yamakawa H; Ogura T; Sato S; Nishizawa T; Kawabe R; Oba T; Kato A; Horikoshi M; Akasaka K; Amano M; Kuwano K; Sasaki H; Baba T; Matsushima H
Respir Med; 2020 Oct; 172():106125. PubMed ID: 32911135
[TBL] [Abstract][Full Text] [Related]
10. Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study.
Richardson C; Agrawal R; Lee J; Almagor O; Nelson R; Varga J; Cuttica MJ; Dematte JD; Chang RW; Hinchcliff ME
Semin Arthritis Rheum; 2016 Aug; 46(1):109-14. PubMed ID: 27033049
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
12. Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
Numajiri H; Yoshizaki A; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Sumida H; Asano Y; Kazoe Y; Mawatari K; Kitamori T; Sato S
J Dermatol; 2018 Oct; 45(10):1221-1224. PubMed ID: 30051925
[TBL] [Abstract][Full Text] [Related]
13. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
[TBL] [Abstract][Full Text] [Related]
14. Severity and features of frailty in systemic sclerosis-associated interstitial lung disease.
Guler SA; Kwan JM; Winstone TA; Milne KM; Dunne JV; Wilcox PG; Ryerson CJ
Respir Med; 2017 Aug; 129():1-7. PubMed ID: 28732817
[TBL] [Abstract][Full Text] [Related]
15. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
16. Serum metabolomic profiling reveals potential biomarkers in systemic sclerosis.
Guo M; Liu D; Jiang Y; Chen W; Zhao L; Bao D; Li Y; Distler JHW; Zhu H
Metabolism; 2023 Jul; 144():155587. PubMed ID: 37156409
[TBL] [Abstract][Full Text] [Related]
17. Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosis.
Sakamoto N; Kakugawa T; Hara A; Nakashima S; Yura H; Harada T; Ishimoto H; Yatera K; Kuwatsuka Y; Hara T; Ichinose K; Obase Y; Ishimatsu Y; Kohno S; Mukae H
Respir Res; 2015 Dec; 16():148. PubMed ID: 26654954
[TBL] [Abstract][Full Text] [Related]
18.
He Y; Liu H; Wang S; Chen Y
DNA Cell Biol; 2019 Sep; 38(9):933-944. PubMed ID: 31361540
[TBL] [Abstract][Full Text] [Related]
19. Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung disease.
Saigusa R; Asano Y; Nakamura K; Yamashita T; Ichimura Y; Takahashi T; Toyama T; Taniguchi T; Yoshizaki A; Miyazaki M; Tamaki Z; Sato S
Mod Rheumatol; 2017 Jul; 27(4):618-622. PubMed ID: 27538472
[TBL] [Abstract][Full Text] [Related]
20. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as potential makers for digital ulcers and interstitial lung disease in patients with systemic sclerosis: cross-sectional analysis of data from a prospective cohort study.
Kim A; Kim Y; Kim GT; Ahn E; So MW; Sohn DH; Lee SG
Rheumatol Int; 2020 Jul; 40(7):1071-1079. PubMed ID: 32424613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
